Teva provides medicines that help improve the health of millions of patients in the UK every day.
We provide hundreds of generic medicines which are supplied to the country’s thousands of pharmacies and dispensaries. We also have a presence in the GP surgery and hospitals with medicines to treat multiple sclerosis, cancer, pain, Parkinson’s disease and respiratory disorders like asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis.
We’ve been around for almost 80 years and we're one of the largest supplier of medicines to the National Health Service.
Whether they’re used in hospitals or by GPs, nurses, or independent pharmacists, our medicines are backed by comprehensive advice and information.
Generic medicines save the NHS more than £13 billion in just England and Wales.1 Without Teva and all the other generics companies, the drugs bill would be approximately twice its current level.2
We believe the changes in the NHS give community pharmacy a great opportunity to shape its own destiny and establish itself as a key service provider in the evolving NHS: helping patients take their medicines properly, and helping address public health issues. We believe pharmacy should be involved with what’s happening locally to ensure they protect and develop patient services as well as firmly establish their own patient service provider roles within the NHS.
We’re the kind of people that make things happen, and our teams work across the NHS and beyond. From retail pharmacists, through to dispensing doctors, GPs, specialist consultants, purchasing professionals, hospital pharmacists, NHS decision making bodies and pharmaceutical wholesalers, our teams provide the kind of quality support and service our customers expect and patients need.
We’re here to help and that’s why we’ve created an area dedicated to your most frequently asked questions. If you can’t find what you need there, or in the Summary of Product Characteristics for our medicines you can contact us by this website, by phone or by email.
We actively invest in the research and development of medicines to fulfil unmet medical needs. In specialty medicines we focus on disorders of the central nervous system and pain relief, along with respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease. We invest heavily in investigating potential new treatments for unmed needs with an empahsis on the safety for patients of those potential treatments.
We are always looking to bring new generic medicines to market. As a leader in generics, our strategy is to maintain our extensive portfolio of generic medicines. We have a robust pipeline and will continue to launch new patent-expired therapies when we can.
 http://www.thetimes.co.uk/tto/health/news/article4570428.ece accessed 18.04.18
 P3 magazine Generics Expand Their Impact accessed 22.07.17